Prostate-specific antigen doubling time as a progression criterion in an active surveillance programme for patients with localized prostate cancer

BJU International

Volumn 113, Issue 5 B, 2014, Pages

  Thomsen, Frederik Birkebæk ^a   Christensen, Ib Jarle ^b   Brasso, Klaus ^a   Røder, Martin Andreas ^a   Iversen, Peter ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Active surveillance; Progression criterion; Prostate cancer; PSA doubling time

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER LOCALIZATION; CANCER RISK; CANCER SCREENING; CONTROLLED STUDY; GLEASON SCORE; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; ACTIVE SURVEILLANCE; BLOOD; DISEASE COURSE; MIDDLE AGED; PROGRESSION CRITERION; PROSPECTIVE STUDY; PROSTATE TUMOR; PSA DOUBLING TIME; RISK ASSESSMENT; TIME; WATCHFUL WAITING;

ACTIVE SURVEILLANCE; PROGRESSION CRITERION; PROSTATE CANCER; PSA DOUBLING TIME;

AGED; DISEASE PROGRESSION; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT; TIME FACTORS; WATCHFUL WAITING;

EID: 84902344693     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12367     Document Type: Article

References (29)

1. Center MM, Jemal A, Lortet-Tieulent J et al. International variation in prostate cancer incidence and mortality rates. Eur Urol 2012; 61: 1079-92
2. Brawley OW. Prostate cancer epidemiology in the United States.World J Urol 2012; 30: 195-200
3. Outzen M, Brasso K, Martinussen N et al. Prostate cancer in Denmark 1978-2009 - trends in incidence and mortality. Acta Oncol 2013; 52: 831-6
4. Heidenreich A, Bellmunt J, Bolla M et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011; 59: 61-71
5. Wilt TJ, Brawer MK, Jones KM et al. Radical prostatectomy versus observation for localized prostate cancer.N Engl J Med 2012; 367: 203-13
6. Choo R, Klotz L, Danjoux C et al. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol 2002; 167: 1664-9 (Pubitemid 34240696)
7. Lees K, Durve M, Parker C. Active surveillance in prostate cancer: patient selection and triggers for intervention. Curr Opin Urol 2012; 22: 210-5
8. O'Brien MF, Cronin AM, Fearn PA et al. Evaluation of prediagnostic prostate-specific antigen dynamics as predictors of death from prostate cancer in patients treated conservatively. Int J Cancer 2011; 128: 2373-81
9. Thomsen FB, Roder MA, Hvarness H, Iversen P, Brasso K. Active surveillance can reduce overtreatment in patients with low-risk prostate cancer. Dan Med J 2013; 60: A4575
10. D'Amico AV, Whittington R, Malkowicz SB et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969-74 (Pubitemid 28445094)
11. Ross AE, Loeb S, Landis P et al. Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol 2010; 28: 2810-6
12. Sengupta S, Myers RP, Slezak JM, Bergstralh EJ, Zincke H, Blute ML. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy. J Urol 2005; 174: 2191-6 (Pubitemid 41611772)
13. Robinson D, Sandblom G, Johansson R et al. PSA kinetics provide improved prediction of survival in metastatic hormone-refractory prostate cancer. Urology 2008; 72: 903-7
14. Fall K, Garmo H, Andren O et al. Prostate-specific antigen levels as a predictor of lethal prostate cancer. J Natl Cancer Inst 2007; 99: 526-32 (Pubitemid 47073555)
15. Bastian PJ, Carter BH, Bjartell A et al. Insignificant prostate cancer and active surveillance: from definition to clinical implications. Eur Urol 2009; 55: 1321-30
16. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010; 28: 126-31
17. Klotz L. Active surveillance: the Canadian experience. Curr Opin Urol 2012; 22: 222-30
18. Bul M, Zhu X, Valdagni R et al. Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. Eur Urol 2013; 63: 597-603
19. Oesterling JE, Rice DC, Glenski WJ, Bergstralh EJ. Effect of cystoscopy, prostate biopsy, and transurethral resection of prostate on serum prostate-specific antigen concentration. Urology 1993; 42: 276-82 (Pubitemid 23270933)
20. Yuan JJ, Coplen DE, Petros JA et al. Effects of rectal examination, prostatic massage, ultrasonography and needle biopsy on serum prostate specific antigen levels. J Urol 1992; 147 (3 Pt 2): 810-4
21. Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991; 145: 907-23
22. Stamey TA, McNeal JE, Freiha FS, Redwine E. Morphometric and clinical studies on 68 consecutive radical prostatectomies. J Urol 1988; 139: 1235-41
23. Stamey TA, Kabalin JN, McNeal JE et al. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. J Urol 1989; 141: 1076-83 (Pubitemid 19124201)
24. Choo R, Deboer G, Klotz L et al. PSA doubling time of prostate carcinoma managed with watchful observation alone. Int J Radiat Oncol Biol Phys 2001; 50: 615-20 (Pubitemid 32519594)
25. Arlen PM, Bianco F, Dahut WL et al. Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. J Urol 2008; 179: 2181-5
26. Beauval JB, Ploussard G, Soulie M et al. Pathologic findings in radical prostatectomy specimens from patients eligible for active surveillance with highly selective criteria: a multicenter study. Urology 2012; 80: 656-60
27. El Hajj A, Ploussard G, de la Taille A et al. Analysis of outcomes after radical prostatectomy in patients eligible for active surveillance (PRIAS). BJU Int 2013; 111: 53-9
28. O'Brien MF, Cronin AM, Fearn PA et al. Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy. J Clin Oncol 2009; 27: 3591-7
29. Maruyama S, Shinohara N, Abe T, Sazawa A, Nonomura K. Can PSA doubling time exactly predict the candidates for active surveillance in patients with low-risk prostate cancer? J Clin Oncol 2012; 30 (5 Suppl. [Februarary 10 Supplement]), abstr 65. Journal of Clinical Oncology, 2012 Genitourinary Cancers Symposium